.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AB06_Ganciclovir.Ganciclovir .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AB06_Ganciclovir.Ganciclovir| name: | Ganciclovir | |
| ATC code: | J05AB06 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 350 | mg |
| volume of distribution: | 0.69 | L |
| clearance: | 4.6 | mL/min/kg |
| other parameters in model implementation | ||
Ganciclovir is an antiviral medication used primarily to treat and prevent cytomegalovirus (CMV) infections, especially in immunocompromised patients such as those with HIV/AIDS or transplant recipients. It is an approved drug and is still widely used in clinical practice for CMV infections.
Reported pharmacokinetic parameters for adult immunocompetent volunteers following a single intravenous dose of 5 mg/kg.
Nguyen, T, et al., & Hirt, D (2021). Population Pharmacokinetics of Intravenous Ganciclovir and Oral Valganciclovir in a Pediatric Population To Optimize Dosing Regimens. Antimicrobial agents and chemotherapy 65(3) –. DOI:10.1128/AAC.02254-20 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33318012
Selby, PR, et al., & Roberts, JA (2023). Population Pharmacokinetics of Ganciclovir in Allogeneic Hematopoietic Stem Cell Transplant Patients. Antimicrobial agents and chemotherapy 67(3) e0155022–None. DOI:10.1128/aac.01550-22 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36815858
Li, S, et al., & Wang, Y (2020). Population Pharmacokinetics and Dose Optimization of Ganciclovir in Critically Ill Children. Frontiers in pharmacology 11 614164–None. DOI:10.3389/fphar.2020.614164 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33536921